From Name

From Email

To Name

To Email

Message

FDA approves Guardant’s tumor-sequencing blood test as a Tagrisso lung cancer diagnostic

from Fierce Biotech

FDA approves Guardant’s tumor-sequencing blood test as a Tagrisso lung cancer diagnostic Fierce Biotech Guardant Health received a milestone approval from the FDA for its cancer test, as the first liquid biopsy able to genetically profile solid tumors anywhere in the body through a single blood draw. READ MORE

more